| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| T Cell Non-Hodgkin Lymphoma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lymphoma | |||||
| Lymphoma, Non-Hodgkin | |||||
| Lymphoma, T-Cell | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunoproliferative Disorders | |||||
| Lymphatic Diseases | |||||
| Lymphoproliferative Disorders | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| 4 | Interventions listed in this trial | ||||
| Imatinib mesylate | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Imatinib | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Dana-Farber Cancer Institute | |||||
| Brigham and Women's Hospital | |||||
| Novartis | |||||
|
